Autologous T-cell vaccines materials and methods

Details Autologous T-cell vaccines materials and methods Autologous T-cell vaccines materials and methods

2001-09-14

2010-02-09

Ewoldt, G. R (Department: 1644)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Reexamination Certificate

active

07658926

ABSTRACT:
The present invention relates to improved autologous T cell vaccines and methods for their production. The invention is also directed to methods for treating T cell associated diseases such as multiple sclerosis are rheumatoid arthritis using autologous T cell vaccines.

REFERENCES:
patent: 4550086 (1985-10-01), Reinherz et al.
patent: 4608365 (1986-08-01), Engel
patent: 4677061 (1987-06-01), Rose et al.
patent: 4897389 (1990-01-01), Aroonsakul
patent: 4898856 (1990-02-01), Aroonsakul
patent: 4898857 (1990-02-01), Aroonsakul
patent: 4902680 (1990-02-01), Aroonsakul
patent: 4996194 (1991-02-01), Cohen et al.
patent: 5039660 (1991-08-01), Leonard et al.
patent: 5112810 (1992-05-01), Nagai et al.
patent: 5211952 (1993-05-01), Spicer et al.
patent: 5242687 (1993-09-01), Tykocinski
patent: 5298396 (1994-03-01), Kotzin et al.
patent: 5340584 (1994-08-01), Spicer et al.
patent: 5445939 (1995-08-01), Anderson
patent: 5480895 (1996-01-01), Friedman et al.
patent: 5494899 (1996-02-01), Kincade et al.
patent: 5545716 (1996-08-01), Johnson et al.
patent: 5552300 (1996-09-01), Makrides et al.
patent: 5554595 (1996-09-01), Kincade et al.
patent: 5569585 (1996-10-01), Goodwin et al.
patent: 5614192 (1997-03-01), Vandenbark
patent: 5643572 (1997-07-01), Byers et al.
patent: 5656446 (1997-08-01), Anderson
patent: 5668117 (1997-09-01), Shapiro
patent: 5674487 (1997-10-01), Smith et al.
patent: 5716946 (1998-02-01), DeLuca et al.
patent: 5723503 (1998-03-01), Smith et al.
patent: 5750356 (1998-05-01), Spack et al.
patent: 5766920 (1998-06-01), Babbitt et al.
patent: 5776459 (1998-07-01), Vandenbark
patent: 5776708 (1998-07-01), Kotzin et al.
patent: 5817622 (1998-10-01), Johnson et al.
patent: 5837246 (1998-11-01), Howell et al.
patent: 5843689 (1998-12-01), Anderson et al.
patent: 5849886 (1998-12-01), Määttäet al.
patent: 5858364 (1999-01-01), Weiner et al.
patent: 5861164 (1999-01-01), Howell et al.
patent: 5869057 (1999-02-01), Rock
patent: 5874531 (1999-02-01), Strominger et al.
patent: 6007815 (1999-12-01), Howell et al.
patent: 6033661 (2000-03-01), Smith et al.
patent: 6043236 (2000-03-01), Brattsand et al.
patent: 6054292 (2000-04-01), Hillman et al.
patent: 6083503 (2000-07-01), Lenardo
patent: 6083521 (2000-07-01), Acemoglu et al.
patent: 6090387 (2000-07-01), Howell et al.
patent: 6096314 (2000-08-01), Cohen et al.
patent: 6114388 (2000-09-01), Geffard
patent: 6130087 (2000-10-01), Srivastava et al.
patent: 6159470 (2000-12-01), Howell et al.
patent: 6187750 (2001-02-01), Chein
patent: 6207147 (2001-03-01), Hiserodt
patent: 6207645 (2001-03-01), Howell et al.
patent: 6218132 (2001-04-01), Spack et al.
patent: 6218166 (2001-04-01), Ravindranath et al.
patent: 6221352 (2001-04-01), Howell et al.
patent: 6303314 (2001-10-01), Zang
patent: 6489299 (2002-12-01), Steinman et al.
patent: 6746670 (2004-06-01), Levings et al.
patent: 6806258 (2004-10-01), Monia
patent: 2001/0031253 (2001-10-01), Gruenberg
patent: 2002/0009448 (2002-01-01), Weiner et al.
patent: 2002/0072493 (2002-06-01), Eisenbach-Schwartz et al.
patent: 2003/0091578 (2003-05-01), Zhang
patent: 2003/0153073 (2003-08-01), Rogers et al.
patent: WO 91/15225 (1991-10-01), None
patent: WO 94/26876 (1994-11-01), None
patent: WO 99/13904 (1999-03-01), None
patent: WO 00/14116 (2000-03-01), None
patent: PCT/US00/22988 (2000-08-01), None
patent: PCT/US02/28874 (2002-09-01), None
Van Der Aa, A., et al. Cli. Exp. Immunol. 2003; 131:155-168.
Zhang, J.Z., et al. Neurology, 2000;54(7) Suppl. 3, A23.
Allegretta M, Nicklas JA, Sriam S, Albertini RJ (1990) T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 247:718-721.
Ben-Nun A, Wekerle H, Cohen IR (1981) The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomylitis. Eur J Immunol 11:195-204.
Ben-Nun A, Wekerle H, Cohen IR (1981) Vaccination against autoimmune encephalomyelitis with T lymphocyte line cells reactive against myelin basic protein. Nature 292:60-61.
Chou YK, Bourdette DN, Offner H, Vandenbark AA (1992) Frequency of T cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis. J Neuroimmunol 38:105-114.
Correale et al. (2000). T cell vaccination in secondary progressive multiple sclerosis. J. Neuroimmunol. 107:130-139.
European Study Group on interferon beta-1b in secondary progressive MS (1998) Placebo-controlled multicentre randomized trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352:1491-1497.
Genain (1995). Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J. Clin. Invest. 96:2966-2974.
Hafler et al. (1992). T cell vaccination in multiple sclerosis: a preliminary report. Clinical Immunol. and Immunopathology 62:307-313.
Hong et al. (1999). A common T cell receptor V-D-J sequence in V∃13.1 T cells recognizing an immunodominant peptide of myelin basic protein in multiple sclerosis. J. Immunol. 163:3530-3538.
Hong et al. (2000). Reactivity and Regulatory Properties of Human Ant-Idiotypic Antibodies Induced by T cell Vaccination. J. Immunol. 165:6858-6864.
Jacobs (1996). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39:285-294.
Kerlero de Rosbo et. al. (1993) Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein. J. Clin. Invest. 92: 2602-2608.
Lider (1988). Anti-idiotypïc network induced by T cell vaccination against experimental autoimmune encephalomyelitis. Science 239:181-183.
Linder et al. (1999) Brain 122: 2089.
Lohse AW, Moi F, Karin N, Cohen IR (1989) Control of experimental autoimmune encephalomyelitis by T cells responding to activated T cells. Science 244:820-822.
Markovic-Plese et al. (1995), T cell recognition of immunodominant and cryptic proteolipid protein epitopes in humans. J. Immunol. 155:982-992.
Medaer (1995). Depletion of myelin basic protein-reactive T cells by T cell vaccination: A pilot clinical trial in multiple sclerosis. Lancet 346:807-808.
Ota et al. (1990). T cell recognition of an immunodominant MBP epitope in multiple sclerosis. Nature 346:183-187.
Offner et al. (1989). Lymphocyte vaccination against experimental autoimmune encephalomyelitis: evaluation of vaccination protocols. J. Neuroimmunol. 21: 13-22.
Poser et al. (1983). New Diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann. Neurol. 13:227-231.
Scheltens et al. (1992). White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer's disease. Brain 115:735-748.
Selmaj et al. (1991). Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions.. J. Clin. Invest. 87:949-954.
Sharief MK, Hentges R (1991). Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N. Engl. J. Med. 325:467-472.
Stinissen et al. (1997). Autoimmune pathogenesis of multiple sclerosis: role of autoreactive T lymphocytes and new immunotherapeutic strategies. Crit. Rev. Immunol. 17:33-75.
The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurol 43:655-661.
Tejada-Simon et al. International Immunology, vol. 12, No. 12: 1641-1650.
Tejada-Simon et al. (2001) Reactivity pattern and cytokine profile of T cells primed by myelin peptides in multiple sclerosis and healthy individuals. Eur. J. Immunol. 31:907-917.
Trotter at al. (1998). T cell recognition of myelin proteolipid protein and myelin proteolipid protein peptides in the peripheral blood of multiple sclerosis and control subjects. J. Neuroimmunology 84:172-178.
Trotter et al. (1997). HPRT mutant T-cell lines from multiple sclerosis patients recognize myelin proteolipid protein peptides. J. Neuroimmunol. 75:95-103.
Truyen et al. (1990). Improved correlation of magnetic resonance imag

Affiliated with

Also associated with

Rating

Autologous T-cell vaccines materials and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Autologous T-cell vaccines materials and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Autologous T-cell vaccines materials and methods will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4181683